European Optimism Defies Greece, Ukraine And GDP Views
at Investor's Business Daily - Fri Feb 13, 4:45PM CST
Markets in Europe finished Friday with modest gains for the week after navigating a rush of historic news events. Those events involved another cease-fire in Ukraine's civil war, talks regarding the status of Greece's bailout and fourth-quarter GDP...
MNK: 115.01 (+2.51), CRH: 28.02 (-0.09), KING: 16.70 (+1.96)
FDA accepts Pfizer's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:22AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
6 Big Pharmaceutical Companies You Don't Want In Your Portfolio
at The Street - Tue Feb 10, 7:17AM CST
Which big pharmaceutical stocks should investors stay away from in 2015?
MNK: 115.01 (+2.51), ENDP: 84.01 (+1.12), JAZZ: 169.69 (+6.89), AZN: 69.96 (+0.20), SLXP: 152.35 (+3.17), GSK: 47.94 (+1.99)
Healthcare stock screen of the month: Accelerating after-tax margins
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 11:21AM CST
MNK: 115.01 (+2.51), BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), BCR: 175.38 (+0.50), EVHC: 36.20 (-0.09), TMO: 127.61 (+0.78), CAH: 86.08 (+0.04), UTHR: 151.11 (+3.59), ILMN: 198.54 (+1.81), ACOR: 36.14 (-0.51), LCI: 57.78 (-0.91), JAZZ: 169.69 (+6.89), SHPG: 239.82 (+6.11), CPHD: 59.62 (+0.72), SYK: 94.51 (+1.14)
Analysts remain bullish on Mallinkrodt
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 12:13PM CST
MNK: 115.01 (+2.51)
Texas AD investigating Mallinckrodt Medicaid pricing
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 9:34AM CST
MNK: 115.01 (+2.51)
Mallinckrodt posts better non-GAAP adjusted net income of USD213.8m in Q1 Fiscal 2015
M2 - Wed Feb 04, 5:28AM CST
Biopharmaceutical company Mallinckrodt (NYSE:MNK) on Tuesday announced improved non-GAAP adjusted net income of USD213.8m for the Q1 fiscal 2015 ended 26 December 2014.
MNK: 115.01 (+2.51)
Mallinckrodt earnings mixed
at Investor's Business Daily - Tue Feb 03, 5:40PM CST
The specialty-drug maker said EPS minus 1-time items for fiscal Q1 ended Dec. 26 more than doubled from a year ago to $1.84, beating views by 26 cents. Mallinckrodt's (MNK) sales rose 60% to $866.3 mil, about $20 mil shy of forecasts. On an earnings...
MNK: 115.01 (+2.51)
Akorn, Actavis Near Buy Points Amid Market Turbulence
at Investor's Business Daily - Tue Feb 03, 4:11PM CST
Two of the three generic drug makers in the Spotlight screen remain near buy points amid the market's recent turbulence. Akorn (AKRX) has been seesawing around a 42.64 early buy point of an irregular pattern. The stock cleared the entry Jan. 16, but...
MNK: 115.01 (+2.51), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25)
Mylan to Buy Famy Care Businesses, Boost Women's Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 3:35PM CST
Mylan (MYL) is set to acquire Indian drug maker Famy Care Limited's certain female reproductive health care businesses to expand its line of women's health portfolio.
MNK: 115.01 (+2.51), IPXL: 39.51 (+0.69), ABT: 46.09 (+0.87), MYL: 55.85 (+1.34)
Mallinckrodt's Mixed Q1 Stokes Analyst Worries
at Investor's Business Daily - Tue Feb 03, 1:09PM CST
Specialty-drug maker Mallinckrodt (MNK) reported mixed fiscal Q1 results Tuesday, sending the stock down as much as 6%. In the quarter ended Dec. 26, Mallinckrodt's earnings excluding one-time items more than doubled over the year-earlier quarter to...
MNK: 115.01 (+2.51), JNJ: 99.62 (+1.18)
Mallinckrodt's (MNK) CEO Mark Trudeau on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 03, 12:39PM CST
MNK: 115.01 (+2.51)
Mallinckrodt (MNK) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Tue Feb 03, 10:38AM CST
The following Mallinckrodt (MNK) conference call took place on February 3, 2015, 08:30 AM ET. This is a transcript of that earnings call:
MNK: 115.01 (+2.51)
Mallinckrodt Beats on Q1 Earnings, Sales Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 10:03AM CST
Mallinckrodt plc (MNK) reported adjusted earnings of $1.84 per share in the first quarter of fiscal 2015 (ended Dec 26, 2014), beating the Zacks Consensus Estimate of $1.57.
IPXL: 39.51 (+0.69), MNK: 115.01 (+2.51), ACT: 285.37 (+3.71), BIOD: 1.38 (-0.14)
Mallinckrodt (MNK) Shows Signs Of Being Water-Logged And Getting Wetter
at The Street - Tue Feb 03, 9:21AM CST
Trade-Ideas LLC identified Mallinckrodt (MNK) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
MNK: 115.01 (+2.51)
Mallinckrodt ups revenues 60% in FQ1
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:25AM CST
MNK: 115.01 (+2.51)
Mallinckrodt Beats on Q1 Earnings Boosted by Acquisitions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 7:37AM CST
Mallinckrodt Beats on Q1 Earnings Boosted by Acquisitions
MNK: 115.01 (+2.51)
Mallinckrodt beats 1Q profit forecasts
Automated Insights - Tue Feb 03, 6:39AM CST
DUBLIN (AP) _ Mallinckrodt PLC (MNK) on Tuesday reported fiscal first-quarter earnings of $92.7 million.
MNK: 115.01 (+2.51)
Mallinckrodt beats by $0.26, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 6:03AM CST
MNK: 115.01 (+2.51)